Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for cognitive impairment related to white matter injury in cerebral small vessel disease
ChiCTR2300069867Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of pentoxifylline in Cerebral Small Vessel Disease (CSVD) and subcortical vascular cognitive impairment (SVCI) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: FLAIR MRI assessment of white matter lesions. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
pentoxifylline
03
Conditions
Cerebral Small Vessel Disease (CSVD)subcortical vascular cognitive impairment (SVCI)
Beyond the preview
Go deeper on ChiCTR2300069867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069867.